Phase 2Recruiting
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis
- Sponsor
- Zomagen Biosciences Ltd. (Industry)
- Enrolment
- 50 planned
- Conditions
- Recurrent Pericarditis
- Interventions
- VTX2735; VTX2735; VTX2735; VTX2735; VTX2735
- Ages
- adults, older adults
- Registry
- NCT06836232
Full record on ClinicalTrials.gov
From the registry
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period Cohort B will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C * A 14-day Follow-Up Period…
Primary outcomes
- Safety and tolerability of VTX2735
History
Primary completion expected
Last registry update
Registered
Started